Pfizer (PFE) and Valneva (VLA FP) announce Lyme Disease vaccine candidate demonstrates strong efficacy in Phase 3 VALOR trial
Importance
Level 1
- Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above
- The investigational vaccine candidate was well tolerated with no safety concerns identified at time of analysis
- Overall, results strengthen confidence in the vaccine candidate and Pfizer is planning submissions to regulatory authorities
#PFIZER INC#PFE.US#VALNEVA SE#VLA.FP#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#PFE#GLOBAL EQUITIES